AVXL
NASDAQ · Biotechnology
Anavex Life Sciences Corp
$2.89
-1.30 (-31.03%)
Financial Highlights (FY 2025)
Revenue
62.53M
Net Income
10.24M
Gross Margin
60.5%
Profit Margin
16.4%
Rev Growth
+23.0%
D/E Ratio
0.80
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 60.5% | 60.5% | 60.5% |
| Operating Margin | 20.5% | 18.5% | 16.5% |
| Profit Margin | 16.4% | 16.7% | 19.0% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 62.53M | 56.87M | 56.55M |
| Gross Profit | 37.83M | 34.41M | 34.21M |
| Operating Income | 12.80M | 10.55M | 9.34M |
| Net Income | 10.24M | 9.50M | 10.72M |
| Gross Margin | 60.5% | 60.5% | 60.5% |
| Operating Margin | 20.5% | 18.5% | 16.5% |
| Profit Margin | 16.4% | 16.7% | 19.0% |
| Rev Growth | +23.0% | -7.3% | -7.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 148.71M | 159.64M | 129.30M |
| Total Equity | 185.46M | 160.49M | 169.59M |
| D/E Ratio | 0.80 | 0.99 | 0.76 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 18.97M | 15.63M | 16.61M |
| Free Cash Flow | 7.70M | 5.60M | 6.46M |